Electronic nicotine delivery systems use is associated with multi-omic biomarkers and prospective cardiopulmonary health outcomes

Andrew Gregory[1], Zhonghui Xu[1], Katherine Pratte[2], Seth Berman[1], Robin Lu[1], Rahul Suryadevara[1], Robert Chase[1], Jeong H. Yun[1,3], Aabida Saferali[1], Craig P. Hersh[1,3], Edwin K. Silverman[1,3], Russell P. Bowler[4], Laura Crotty-Alexander[5,6], Adel Boueiz[1,3*], Peter J. Castaldi[1,7*]

[1]Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; [2]Department of Biostatistics, National Jewish Health, Denver, CO; [3]Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; [4]Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO; [5]Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego (UCSD), La Jolla, CA; [6]Department of Medicine, Pulmonary Critical Care Section, Veterans Affairs (VA) San Diego Healthcare System, La Jolla, CA; [7]Division of General Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

* Equal contribution

Corresponding Author: Peter J. Castaldi, MD, MSc, Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, Email: peter.castaldi@channing.harvard.edu

Authors' email addresses: Andrew Gregory (andrew.gregory@channing.harvard.edu), Zhonghui Xu (zhonghui.xu@channing.harvard.edu), Katherine Pratte (PratteK@njhealth.org), Seth Berman (seth.berman@channing.harvard.edu), Robin Lu (robin.lu@channing.harvard.edu), Rahul Suryadevara (rahul.suryadevara@channing.harvard.edu), Robert Chase (robert.chase@channing.harvard.edu), Jeong H. Yun (jeong.yun@channing.harvard.edu), Aabida Saferali (aabida.saferali@channing.harvard.edu), Craig P. Hersh (craig.hersh@channing.harvard.edu), Edwin K. Silverman (ed.silverman@channing.harvard.edu), Russell P. Bowler (BowlerR@njhealth.org), Laura Crotty-Alexander (lca@ucsd.edu), Adel Boueiz (adel.boueiz@channing.harvard.edu), Peter J. Castaldi (peter.castaldi@channing.harvard.edu)

Author Contributions:

Drs. Boueiz and Castaldi had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, had authority over manuscript preparation and the decision to submit the manuscript for publication.

Study concept and design: Gregory, Xu, Boueiz, Castaldi

Acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: Gregory, Boueiz, Castaldi

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Gregory, Xu, Castaldi, Boueiz

Obtained funding: Boueiz, Castaldi, Silverman

Study supervision: All authors

All authors gave final approval of the version to be published.

Funding Sources: This work was supported by NHLBI K08HL141601, K08HL146972, K01HL157613, R01HL124233, U01 HL089897, R01 HL147326, and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.

Competing Interests: EKS and PJC have received grant support from GlaxoSmithKline and Bayer. JY has received institutional grant support from Bayer and personal fees from Bride Biotherapeutics outside the submitted work.

Manuscript Word Count: 3,702

Keywords: biomarkers, vaping, ENDS, e-cigarettes, smoking, genomics

<u>Abstract (250/250 words)</u>

Introduction: Electronic nicotine delivery systems (ENDS) are driving an epidemic of vaping. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking), will facilitate studies of the health effects of vaping. We conducted a blood biomarker discovery study for vaping and dual use in a longitudinal cohort of current and former adult smokers with high-throughput transcriptomic and proteomic data, and we tested biomarkers for association to multiple health outcomes.

Methods: We studied 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data according to their self-reported current vaping and smoking behavior. Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes.

Results: We identified 3 transcriptomic and 3 proteomic associations to vaping, and 90 transcriptomic and 100 proteomic associations to dual use *(FDR 10%)*. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (3 transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (2 transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality and respiratory exacerbations.

Conclusion: Vaping and dual use are associated with multiple blood-based biomarkers that are also associated with adverse health outcomes.

What is already known on this topic: Vaping and dual use result in measurable molecular changes in many tissues, including blood. Vaping causes short and longer term health effects, and identification of biomarker that can be used as surrogate outcomes in clinical trials would be a useful tool for regulation of electronic nicotine delivery systems (ENDS).

What this study adds: This study identifies a total of 196 significant associations between blood molecular measurements and vaping and/or dual use in 3,892 adult subjects from the COPDGene Study. A number of these putative biomarkers are also significantly associated to prospective development of lung and cardiovascular disease observed in the long-term follow-up of these subjects.

How this study might affect research, practice or policy: The putative biomarkers identified in this study are promising candidates for further validation and evaluation in independent cohorts with the goal of identifying biomarker surrogate outcomes for use in studies of ENDS.

Introduction

The high prevalence of electronic cigarette use (vaping) among both adolescents[1] and adult cigarette smokers[2] is a major public health concern. Electronic cigarettes, also referred to as electronic nicotine delivery systems (ENDS), were initially marketed as a means of smoking reduction, with the hope that their effects on the health of smokers would be a net positive. However, vaping is associated with acute respiratory symptoms[3–5] and lung injury[6,7] and is likely to be associated with long-term adverse health effects. Some vaping and tobacco companies are targeting non-smokers and young people as a profitable demographic and promoting ENDS use beyond the population of established smokers, resulting in an ongoing epidemic of vaping in adolescents and non-smoking adults that is clearly detrimental to public health[8–10].

The Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and Drug Administration (FDA) regulatory oversight over tobacco products which, by the FDA Deeming Regulation of 2016, includes ENDS. Thus, the FDA is responsible for reviewing the safety of all ENDS products introduced to market after February 15, 2007. To facilitate this review process, it is important to determine whether there are validated biomarkers of ENDS use and combined use of ENDS and cigarettes (dual use). While biomarkers of vaping and dual use have been reported, few if any vaping biomarkers have been assessed for their association to prospective health outcomes, and the predictive performance of multi-biomarker panels has not been assessed. In this paper, the term biomarker refers to molecular measurements tested for association to vaping or smoking exposure, which we distinguish from validated biomarkers in which a specific association has been demonstrated in multiple studies. Validated biomarkers that are also predictive of prospective health events can be considered for use as surrogate

outcomes in safety and health assessments[11,12]. which would be a useful tool for evaluating the health effects of an increasingly diverse array of ENDS products. Thus goal of this study is to establish a set of candidate biomarkers for future validation and further study as potential surrogate outcomes.

We hypothesized that vaping and dual use are associated to multi-omic biomarkers, and that a subset of these biomarkers are associated with the development of pulmonary and cardiovascular disease. We conducted high throughput transcriptomic and proteomic analysis that identified over one hundred biomarkers associated with vaping and dual use in a cohort of adult current and former smokers in the COPDGene study. We tested these biomarkers for association to prospective spirometric changes, mortality, and incident cardiovascular disease, identifying dozens of significantly associated biomarkers. We also investigated the extent to which multimarker panels can predict vaping and smoking status and the development of prospective health outcomes.

Methods

Study description

The COPDGene study recruited 10,198 non-Hispanic White and Black smokers with at least 10 pack-years of lifetime cigarette smoking history at 21 U.S. clinical centers (NCT00608764, www.copdgene.org)[13] between 2007 and 2011. COPDGene obtained 5-year follow-up and is currently obtaining 10-year follow-up of available subjects to collect longitudinal data on study participants. 6,756 subjects completed their 5-year study visit (Visit 2) and the 10-year study visit (Visit 3) is ongoing. Data collected includes questionnaires,

spirometry, and self-reported smoking and vaping behaviors. At visit 2, whole blood RNA sequencing (RNA-seq), plasma protein measurements (SOMAscan version 4.0 (5.0K) assay for human plasma), and plasma cotinine were obtained from a subset of subjects. Throughout the study, subjects were also regularly contacted via the phone or internet as part of the COPDGene Longitudinal Follow-up (LFU) program to assess interval events, including respiratory exacerbations, incident comorbidities, and mortality. Definitions of respiratory exacerbations, incident comorbidities, and mortality assessment are included in the Supplement. Written informed consents were obtained for all subjects, and each clinical site obtained institutional review board approval.

Vaping and smoking groups

Starting from Visit 2, vaping was determined by self-report including ever use, current use, intensity, cartridge size, brand, and flavoring. The four comparison groups for biomarker discovery (vapers, current smokers, former smokers, and dual users) were defined based on the subjects' questionnaire responses at Visit 2. Vapers were subjects who reported using at least one e-cigarette within the prior week and had a history of smoking tobacco cigarettes, but not within the last 30 days. Current smokers reported current smoking with an average of at least one cigarette per day without any e-cigarette use (current smokers). Dual users were vapers who also reported current smoking, and former smokers were defined as those who reported a history of smoking but did meet criteria for current smoking or vaping. In most of the reported analyses, former smokers are used as the reference group. Differences in baseline characteristics between

groups were assessed with Kruskal-Wallis and chi-square tests for continuous and categorical measurements, respectively.

RNA-sequencing

Total blood RNA was collected from subjects at Visit 2 in PAXgene TM Blood RNA tubes from the Qiagen PreAnalytiX PAXgene Blood miRNA Kit (Qiagen, Valencia, CA). The gene count data used for this analysis is available in GEO (accession number GSE158699). Counts were transformed to log2 counts per million (CPM) values and quantile-normalized. Additional details are included in the Supplement.

Measurement of plasma protein biomarkers

At Visit 2, plasma samples were assayed for 4,979 proteins in 5,670 COPDGene participants using the SOMAscan Human Plasma 5.0K assay, a multiplex aptamer-based assay (SomaLogic, Boulder, Colorado)[14]. The standardization process included within-plate hybridization, median signal normalization, and plate scaling and calibration of SOMAmers to control for inter-assay variation between analytes and batch differences between plates. Inverse normal transformation was applied to all protein measurements prior to association analysis.

Cotinine measurements

Plasma metabolite measurements were obtained from plasma for 1,136 subjects at COPDGene Visit 2 using the Metabolon Global Metabolomics Platform (Durham, NC, USA)[15]. Metabolite levels were quantified as raw area counts. Plasma cotinine levels were evaluated and missing values were assigned a level of half the lowest detected amount of cotinine. Values were log transformed, and differences in cotinine distribution between groups were evaluated with the Wilcoxon Rank Sum test. COPDGene metabolomic data are available in the Metabolomics Workbench of the NIH Common Fund's National Metabolomics Data Repository (Study ID ST001443; https://www.metabolomicsworkbench.org).

RNA-seq differential expression and protein association analyses

We used the limma R package (v3.38.3)[16] to test for the associations between RNA transcripts and the vaping/smoking groups, using the former smoker group as the reference and adjusting for age, sex, race, and library preparation batch effects. The voom function was used in the RNA-seq analysis. Regression models for protein expression used identical covariates, with the exception that library preparation batch effects were replaced with a variable for clinical center. For both differential gene expression and protein association analyses, we corrected for multiple testing with the Benjamini-Hochberg method and applied a threshold of significance of a false discovery rate (FDR) of 10%[17]. For selected genes and proteins that were associated in only one contrast (vaping or dual only associations), we also conducted association analyses for the contrasts of vapers versus smokers, vapers versus dual users, and dual users versus smokers. Gene set enrichment analysis were performed using the fast gene set enrichment analysis (FGSEA) R package (v3.12)[18]. Further details are included in the Supplement.

Associations of transcripts and proteins to health outcomes

Biomarkers significantly associated with vaping or dual use were tested for association to prospective health-related outcomes, namely change in FEV1 (absolute volume and percent change from baseline), prospective exacerbations, all-cause and respiratory mortality, and incident CVD. FEV_1 changes were computed by subtracting Visit 2 from Visit 3 FEV_1 values and dividing this difference by the number of years between both visits. FEV_1 changes were calculated as both absolute and relative (as a percentage of the Visit 2 measurement) values. Data points >5 standard deviations from the mean for either change in FEV1 measure were excluded from analysis.

The FEV1 outcomes were evaluated using multivariable linear regression models, and the time-to-event outcomes were evaluated using Cox-proportional hazards models using Visit 2 as the starting point. Analyses were adjusted for sex, race, and age at baseline (Visit 2). For time-to-event outcomes baseline FEV1 % of predicted was included as a covariate. Since the sample sizes of our vaping/smoking groups were small, these association analyses were performed in all available COPDGene study subjects without stratifying by vaping or smoking exposure. The false discovery rate was controlled at 10% using the Benjamini-Hochberg method.

Prediction modeling for vaping status and prospective health outcomes

Predictive models using only transcript and protein biomarkers were constructed for vaping/smoking groups and prospective health outcomes. For categorical and binary outcomes,

linear discriminant analysis (LDA) was used. For change in FEV1 models, elastic net models were constructed. Cross-validation was used to prevent overfitting and estimate predictive performance. Model performance was assessed by cross-validation using the Youden index (sensitivity + specificity - 1), area under the receiver operator characteristic curve (AUROC), and area under the precision recall curve (AUCPR) for binary outcomes. R2 was used to evaluate the performance of change in FEV1 models. Additional details are included in the Supplement.

Results

Baseline characteristics

A visual overview of the study and data flow is included in Supplemental Figures 1 and 2. There were 51 and 77 subjects reporting current vaping only or dual use, respectively, at the COPDGene second study visit. Differences in baseline characteristics of these groups along with the current and former smoker groups are reported in Table 1. The large majority of subjects in the vaping group (80%) reported vaping at least once a day. The dual user group reported lighter vaping on average, with only 42% reporting daily vaping, and their pack-years exposure was similar to the current smoker group. FEV1 % of predicted values were comparable for all groups. Biochemical confirmation of nicotine exposure via analysis of plasma cotinine levels in 853 subjects demonstrated elevated cotinine levels in the vaping, dual use, and smoking groups relative to the former smokers group (Figure 1, Wilcoxon rank sum test $p < 0.005$ for all comparisons). A subset of the former smoker group had elevated levels of nicotine that could be due to use of nicotine replacement therapy or unreported smoking or vaping.

Blood RNA-seq associations to vaping and dual use

A total of 18,303 genes were tested for differential expression analysis of vapers, dual users, and current smokers using the former smoker group as the reference group. The top results from each analysis are shown in Table 2, and complete results are reported in Tables S1-S3. For vapers, three significant associations were identified at an FDR of 10% (Figure 2). Two of these genes (*LINC02470* and *NPHP1)* were expressed at a higher level in vapers than any of the other three groups ($p<0.05$ for all comparisons, Table S4). The third gene, *GPR15* is one of the most well-reported genes upregulated by smoking. This gene is also upregulated in vapers, but to a lesser extent than in either smokers or dual users ($p<0.005$ for all comparisons). Gene set enrichment analysis identified 16 significant MSigDB Hallmark pathways with the top three processes being related to inflammation, oxidative phosphorylation, and heme metabolism (Table 3). For all significant gene sets, enrichment was in the direction of decreased expression in vapers compared to former smokers. Since smoking has been shown to have mixed effects on inflammation, we compared the pattern of gene set enrichment for the Hallmark Inflammation pathway in vapers, smokers, and dual users, and we observed that smoking and dual use show elements of activation and repression of this gene set, the effect of vaping was more clearly downregulation of this pathway (Supplemental Figure 3).

For dual users, 90 differentially expressed genes were identified, and 17 of these genes were significant only in the dual user analysis. All of these 17 genes were also significantly differentially expressed when comparing dual users to current smokers, suggesting that these genes have a distinctive response to dual use ($p<0.005$ for all comparisons, Table S5). Gene set enrichment analysis identified four significant Hallmark pathways related to heme metabolism, oxidative phosphorylation, E2F signaling, and interferon gamma response (Table 3). Complete

results for the vaping, dual use, and smoking analyses including MSigDB Immunologic Signature pathways are presented in Supplemental Tables S6-S8.

Proteomic biomarker associations to vaping and dual use

A total of 4979 SOMAscan aptamers mapping to 4,720 unique proteins were tested for association to vaping and smoking groups. The top significantly associated proteins are shown in Table 2 (see Table S9 for complete results), and violin plots for selected top protein biomarkers associated with vaping or dual use are shown in Figure 3. Three protein biomarkers (EDIL3, DPYL5, and KLK13) were significantly associated with vaping status at a 10% FDR, and DPYL5 expression was found to be higher in vapers compared to each of the other groups ($p<0.05$ for all comparisons, Table S10). One hundred protein biomarkers were associated with dual use, with four (CXA8, Keratin 19, CSKP, and PXDC1) being significantly associated only with dual use. All four of these proteins also showed nominal association ($p<0.05$) in an analysis comparing dual users to current smokers, indicating a distinct response to dual use (Table S11).

Comparison of biomarker associations to vaping, smoking, and dual use

To compare the similarity of the transcriptomic and proteomic responses to each exposure, we constructed pairwise plots of the effect sizes of all significantly associated biomarkers (Figure 4). There was a strong positive correlation between the biomarker responses to smoking and dual use (Pearson's $r = 0.76$ and 0.88 for RNA and protein, respectively), whereas the vaping biomarker profile had low correlation to the profiles for both dual use and

smoking (r between 0.23 and 0.44). Certain biomarkers (LINC02470 and DPYL5 protein) had particularly strong and unique associations with vaping. When we compared effect sizes between RNA and proteomic biomarkers associated with vaping and smoking, the correlation was low (r=0.11) as might be expected given various potential sources of origin for circulating blood proteins.

Classification Accuracy for Vaping/Smoking Behavior Using Biomarker Panels

To determine how well RNA and protein biomarkers could classify subjects according to their vaping/smoking behavior, we used a nested cross-validation approach to provide an unbiased estimate of the classification performance achievable by multi-class prediction models using linear discriminant analysis (LDA). The performance of this model is shown in Table 4, where for each group the task is to distinguish that group from all other groups combined. The model achieved good discrimination for current smokers (Youden index (YI) = 0.81) and former smokers (YI = 0.80) and had statistically significant but less accurate performance for vapers (YI = 0.53) and dual users (YI = 0.55). More detailed metrics for each pairwise contrast (Table S12) demonstrates that the models do better in discriminating vapers from current smokers than former smokers (YI = 0.73 and 0.50, respectively), whereas for dual user models discrimination was better for former smokers (YI = 0.82) than current smokers (YI = 0.34), providing further evidence of the similarity between dual use and current smoking biomarker profiles.

Vaping and Dual Use Biomarkers and Longitudinal outcomes

To determine whether biomarkers of vaping or dual use were associated with prospective health-related outcomes, we tested the 92 RNA transcripts and 101 protein biomarkers associated with vaping and/or dual use for association to multiple health outcomes in all COPDGene subjects. Twenty-one transcripts and 88 protein biomarkers were associated with one or more of the studied outcomes at a 10% FDR level. Of the vaping-associated biomarkers, two (KLK13 and DPYL5) were associated with loss of FEV1, and KLK13 was also associated with mortality. Boxplots for the top four vaping or dual use proteins associated with all-cause mortality are shown in Figure 5, and all significant biomarker associations are shown in Tables S13-S16.

We then determined whether the effect of vaping or dual use on each protein biomarker was consistent with higher or lower risk for each adverse health outcome, and we observed that the direction of the exposure effect was overwhelmingly towards increased risk for adverse health events (Figure 6). Out of 246 total significant associations to health outcomes, 224 (91%) showed concordance between the effect of vaping or dual use and the direction of association to increased risk. Both of the vaping-associated biomarkers (KLK13 and DPYL5) showed concordant effects for higher health risk.

To estimate the accuracy of multi-marker panels of vaping and dual use biomarkers for predicting prospective health outcomes, we constructed predictive models for FEV1 decline, all cause mortality, COPD exacerbations, and incident CVD using only the vaping or dual-use associated RNA and protein biomarkers. Models using the seven vaping-associated biomarkers alone gave non-informative predictions, but models using the 190 dual use-associated biomarkers gave informative predictions with moderate accuracy for FEV1 decline, all-cause mortality and respiratory exacerbations (Table 5).

Replication of previously reported vaping biomarker associations

A recently published review of vaping biomarkers listed 14 inflammatory and matrix degradation protein biomarkers that had been previously associated with vaping[19]. We examined the results from these 14 biomarkers at the RNA and protein level for association to vaping or dual use, and we observed associations at nominal significance ($p<0.05$) for four biomarkers (*IL1B*, ICAM1 RNA and protein, IL-6, and MMP9, see Table S17).

Discussion

Identifying validated biomarkers of vaping and dual use is an important tool for effective regulation of ENDS. This study of adult established smokers identified significant associations of six and 190 blood molecular markers to vaping and dual use, respectively. Because of the comprehensive nature of the ‘omics measurements, we could compare the overall molecular profiles of vaping, dual use, and smoking, which revealed that the vaping profile was substantially different from current smoking, whereas dual use and smoking were similar but not identical. Biomarkers associated with vaping and dual use were also associated with multiple cardiopulmonary health outcomes, and reasonably predictive accuracy for some of these outcomes could be achieved for models using dual use biomarkers.

A previous metabolomic biomarker study by Goniewicz et al. demonstrated that vaping is associated with metabolomic changes, albeit at generally lower levels compared to cigarette smokers or dual users[20]. A recent study of vapers versus non-smokers identified numerous

changes in plasma biomarkers associated with inflammation, oxidative stress, and extracellular matrix degradation[19]. A recent meta-analysis of biomarkers of ENDS versus cigarettes reported a more favorable biomarker profile of ENDS use, though the last author of the study has been reported to have ties to the tobacco industry[21,22]. Another systematic review also reported reduced levels of some biomarkers in ENDS users relative to smokers, but this is not consistent for all biomarkers(Hiler et al. 2021). By examining the correlation in biomarker profiles for vaping, dual use, and smoking, we observed that the vaping profile is largely distinct from both the dual use and smoking profile which are in turn highly correlated to each other. We did however observe multiple examples of shared RNA and protein biomarkers between smoking, vaping, and dual use, such as *GPR15*. We also provided independent validation for previously reported vaping or dual use associations with *IL1B*, ICAM1 RNA and protein, IL-6, and MMP9.

Both vaping and dual use are associated with diverse effects on biological pathways related to aspects of inflammation, oxidative phosphorylation, and coagulation-related pathways. Previous studies have also shown that long non-coding RNAs (lncRNAs) are associated with vaping[23,24], and in our work we identified LINC02470 as a vaping biomarker that has previously been reported to modulate Wnt-beta catenin signaling via exosomal secretion from bladder cancer cells[25]. DPYL5 was uniquely upregulated in vaping subjects and is primarily expressed in brain tissue and glial cells, though it is also expressed at detectable levels in the GI tract. DPYL5 is potentially an important vaping biomarker, because it was also predictive of future loss of lung function. To our knowledge this is the first report of DPYL5 as a specific and clinically relevant biomarker of vaping, a finding that requires further independent validation.

Many of the biomarkers altered by vaping and dual use are also associated with risk of adverse health events such as loss of lung function, respiratory exacerbations, and mortality. For the overwhelming majority of biomarkers, the direction of effect of vaping and dual use was consistent with increased health risk. This extends numerous prior observations linking vaping to a variety of pulmonary symptoms and alterations of cardiovascular physiology[26], providing an important link to longer term health outcomes and suggesting that some of these biomarkers may be useful in assessing health risks of specific vaping devices and e-liquid formulations. For dual use, a multi-marker panel of associated biomarkers achieved modest predictive accuracy for some important outcomes. For vapers, the biomarker profile was more subtle and with our current sample size we did not identify a sufficient number of biomarkers to enable accurate multi-marker prediction of health outcomes.

The strengths of this study are the high-throughput approach to biomarker discovery, the characterization of associations to prospective health events, and the use of machine learning to assess the predictive performance of multimarker panels. Limitations include a modest sample size of vapers and dual users and the lack of independent replication due to lack of available cohorts with similar biomarker data and exposure characterization. Information regarding specific vaping devices and fluids was limited and reflects the challenges posed by the rapid evolution of vaping devices over the study period. Our findings cannot be assumed to generalize to newer generation vaping devices which will require dedicated study, and our findings in adults do not necessarily apply to other important groups such as adolescents.

In conclusion, this study identified over one-hundred transcriptomic and proteomic biomarkers associated with vaping and dual use, and many of these biomarkers are also associated with prospective cardiopulmonary health outcomes. Prediction of health outcomes

using multimarker panels can provide informative prediction with room for improvement, and validation in independent cohorts will increase confidence in individual biomarkers and multi-marker models. Larger-scale studies with greater power would be likely to identify additional biomarkers that could further improve predictive model performance.

Table 1. Baseline characteristics of the vaping and smoking groups

	Current smokers (n = 1,328)	Former smokers (n = 2,436)	Vapers (n = 51)	Dual users (n = 77)	P-value
Age	59.6 (9.5)	68.6 (11.9)	64.6 (10.2)	61.6 (9.9)	< 0.001
Sex, % male	50.5%	52.0%	39.2%	48.1%	0.3
% Non-Hispanic Whites	47.1%	82.4%	88.2%	71.4%	< 0.001
BMI	27.2 (8.4)	28.7 (7.6)	29.2 (9.6)	26.9 (7.1)	< 0.001
Smoking pack-years	41.1 (25.8)	38.0 (29.2)	50.1 (26.3)	45.0 (26.3)	< 0.001
FEV_1 (L)	2.2 (1.1)	2.1 (1.2)	2.1 (1.2)	2.1 (1.2)	< 0.001
FEV_1, % predicted	81.9 (28.0)	82.0 (35.6)	83.2 (32.7)	76.9 (29.7)	0.2
FVC (L)	3.1 (1.4)	3.0 (1.4)	3.1 (1.5)	3.0 (1.5)	0.02
Use of e-cigarettes:					
Less than once a month	NA	NA	0.0%	2.6%	0.3
Less than once a week	NA	NA	0.0%	15.6%	0.003
Some days (1-3 days a week)	NA	NA	4.0%	27.3%	< 0.001
Most days	NA	NA	16.0%	13.0%	0.6
Every day	NA	NA	80.0%	41.6%	< 0.001
Cartridge size:					
0 mg	NA	NA	8.2%	4.0%	0.3
6-8 mg	NA	NA	20.4%	16.0%	0.5
9-12 mg	NA	NA	14.3%	9.3%	0.4
13-16 mg	NA	NA	14.3%	6.7%	0.2
Do not know	NA	NA	22.5%	52.0%	0.001
Other	NA	NA	20.4%	12.0%	0.2
Number of e-cigarettes used (last 24 hours)	NA	NA	10 (16)	3 (10)	< 0.001
Number of cartridges used/week	NA	NA	2 (6)	1 (1)	0.002
E-cigarette brand:					
Blu	NA	NA	4.6%	17.4%	0.04
Henley	NA	NA	2.3%	1.5%	0.7
Joye	NA	NA	0.0%	2.9%	0.3
NJOY	NA	NA	2.3%	8.7%	0.2
V2	NA	NA	2.3%	2.9%	0.8
Other	NA	NA	90.9%	71.0%	0.01
SGRQ Symptom Score	28.7 (40.4)	17.9 (39.0)	15.8 (46.3)	43.5 (48.5)	< 0.001
Respiratory exacerbation	14.4%	17.9%	21.6%	23.4%	0.01
CVD	18.5%	25.8%	15.7%	18.2%	< 0.001

Continuous variables are reported as medians (interquartile ranges). Categorical variables are reported as percentages. Kruskal-Wallis rank sum tests were used for continuous variables. Chi-square tests were used for categorical variables. BMI: Body mass index; CVD: Cardiovascular disease (history of stroke, heart attack, coronary artery disease, coronary artery bypass graft surgery, peripheral artery disease, and/or cardiac angina); Respiratory exacerbation: At least one respiratory exacerbation (acute worsening of respiratory symptoms that required systemic steroids and/or antibiotics) in the previous year; FEV_1: Forced expiratory volume in 1 second; FEV_1, % predicted: Observed FEV1 / Predicted FEV1 based Hankinson reference equation; FVC: Forced vital capacity; SGRQ: St. George's respiratory questionnaire score. % LAA-950: Percentage of CT low attenuation less than -950 HU at end-inspiration using Thirona software; % Segmental airway wall thickness: Percentage of the wall relative to the total bronchial area for the segmental airways. NA = Not applicable.

Table 2. Top 5 differentially associated genes and proteins for vapers, dual users, and current smokers.

	Genes				Proteins			
	Gene	**Ensembl gene ID**	**Log fold change**	**q-value**	**Protein**	**Uniprot ID**	**Mean difference**	**q-value**
Vaping	*GPR15*	ENSG00000154165	0.90	<0.001	EDIL3	O43854	0.52	0.03
	*NPHP1**	ENSG00000144061	0.79	0.05	DPYL5*	Q9BPU6	0.62	0.03
	*LINC02470**	ENSG00000225231	1.37	0.07	Kallikrein 13	Q9UKR3	0.54	0.09
Dual use	*SEMA6B*	ENSG00000167680	2.10	<0.001	Placental alkaline phosphatase	P05187	1.12	<0.001
	MIR124-1HG	ENSG00000253230	2.32	<0.001	PPBN	P10696	0.92	<0.001
	GPR15	ENSG00000154165	1.71	<0.001	LPLC1	Q8TDL5	0.88	<0.001
	LRRN3	ENSG00000173114	1.59	<0.001	PSP-94	P08118	0.88	<0.001
	CTTNBP2	ENSG00000077063	1.52	<0.001	sICAM-5	Q9UMF0	0.84	<0.001
Current smoking	*GPR15*	ENSG00000154165	1.34	<0.001	Placental alkaline phosphatase	P05187	1.00	*<0.001*
	MIR124-1HG	ENSG00000253230	1.79	<0.001	PPBN	P10696	0.89	*<0.001*
	SEMA6B	ENSG00000167680	1.51	<0.001	PSP-94	P08118	0.77	*<0.001*
	LRRN3	ENSG00000173114	1.21	<0.001	LPLC1	Q8TDL5	0.72	*<0.001*
	P2RY6	ENSG00000171631	0.88	<0.001	PIGR	P01833	0.73	*<0.001*

Differential gene expression and protein association analyses was performed for each vaping/smoking group using the former smoker group as reference and adjusting for age, sex, race and batch effects. Up to 5 significant biomarkers are shown. "Uniquely" significant biomarkers (i.e. biomarkers significant at 10% FDR for one contrast but not for any of the other contrasts) are indicated with *. Effect sizes are reported as log fold change for the RNA-seq analysis and mean difference in normalized RFU (relative fluorescence units) for the proteomics analysis. Q-values calculated using the Benjamini-Hochberg procedure implemented in the p.adjust function in R.

Table 3. Top 5 significant (adjusted P-values < 0.1) MSigDB Hallmark pathways from differential gene expression analyses for the vaping and smoking groups.

	MSigDB Hallmark pathway	Pathway ID	Number of genes	NES	Adjusted P-valu
Vaping	Inflammatory Response	M5932	163	-4.10	$6.3x10^{-10}$
	Oxidative Phosphorylation	M5936	200	-4.01	$2.8x10^{-9}$
	Heme Metabolism	M5945	195	-3.82	$2.7x10^{-8}$
	TNF-α Signaling via NF-kB	M5890	179	-3.85	$3.7x10^{-8}$
	Complement	M5921	171	-3.50	$4.0x10^{-7}$
Dual Use	Heme Metabolism	M5945	195	-5.53	$3.9x10^{-17}$
	Oxidative Phosphorylation	M5936	200	-3.70	$1.7x10^{-7}$
	E2F Targets	M5925	199	-3.69	$2.0x10^{-7}$
	Interferon gamma response	M5913	194	-2.90	$1.4x10^{-4}$
Smoking	Heme Metabolism	M5945	195	-8.68	$1.2x10^{-48}$
	MYC Targets V1	M5926	200	3.33	$6.1x10^{-6}$
	Estrogen Response Late	M5907	145	-2.89	$2.2x10^{-4}$
	Xenobiotic Metabolism	M5934	151	-2.86	$3.2x10^{-4}$
	Epithelial mesenchymal transition	M5930	129	-2.86	$3.8x10^{-4}$

Gene set enrichment analysis (GSEA) was performed using the results from the differential expression analysis comparing vapers, dual users, or current smokers to former smokers. Genes were ranked for enrichment analysi by log fold change. The top 5 results from the MSigDB Hallmarks gene sets are shown ordered by p-value. The "number of genes" column is the number of genes associated with the GSEA pathway that could be mapped to the differential expression results. Abbreviations: NES = normalized enrichment score. UV= ultraviolet light.

Table 4. Multi-class prediction of vaping and smoking groups using multi-omic biomarkers

	Integrated RNA-seq and proteomic data			
	Current smokers	Former smokers	Vapers	Dual users
AUROC	0.94	0.94	0.71	0.71
AUPRC	0.85	0.97	0.06	0.04
Youden index	0.81	0.80	0.53	0.55

Linear discrimination analysis models were used to classify vaping and smoking groups. For each group, LDA models are constructed to distinguish that group from the other three using 10-fold nested cross validation (CV) to estimate performance. Abbreviations: AUROC = Area under the receiving operating characteristic curve; AUPRC = Area under the precision-recall curve. The Youden Index (YI) metric was used to summarize the model performance at the optimal cutoff on the area under the receiver operating curve.

Table 5. Performance metrics of prediction models for prospective health outcomes.

Biomarker Panel	Outcome	Sample size (events)	AUROC	AUPR	Youden Index	R2
Dual Use Biomarkers	Δ FEV1 (ml/yr)	642	NA	NA	NA	0.08
	Δ FEV1 (% of baseline)	642	NA	NA	NA	0.17
	Overall mortality	2388 (246)	0.68	0.38	0.36	NA
	Exacerbation >= 1	2231 (811)	0.63	0.51	0.25	NA
	Incident CVD	1700 (183)	0.68	0.34	0.36	NA

Prediction models for the indicated outcomes were constructed using elastic net for change in FEV1 models and linear discriminant analysis for binary outcomes. Δ FEV1 (ml/yr) = (FEV1 at visit 3 - FEV1 at visit 2) / years between visits. Δ FEV1 (% of baseline) = Δ FEV1 (ml/yr) / FEV1 at visit 2. Exacerbation = 1 if subjects reported one of more exacerbation over the follow-up period after visit 2 and 0 otherwise. Incident CVD = 1 if subject reported new diagnosis of CVD after visit 2, and subjects with existing CVD at visit 2 were excluded. AUROC = area under the receiver operator characteristic. AUPR = area under the precision-recall curve. R2 = r-squared.

Figure Legends:

Figure 1. Plasma cotinine levels by vaping/smoking group. In a subset of subjects, plasma metabolomics data was measured using the Metabolon Global Metabolomics Platform. Violin plots of log-transformed cotinine raw area counts are shown. Cotinine levels are significantly higher in all three groups relative to FS (Wilcoxon rank sum $p < 0.005$ for all three comparisons). FS = former smokers. CS = current smokers.

Figure 2. Significantly associated vaping RNA biomarkers. Three RNA biomarkers were significantly associated at 10% FDR in the analysis comparing vapers to former smokers. *NPHP1* and *LINC02470* were significantly associated in the vaping but not the smoking or dual use comparison to former smokers. *GPR15* is significantly elevated in all three groups relative to former smokers, but its expression is relatively lower in vapers relative to dual users and current smokers ($p<0.005$ for all comparisons).

Figure 3. Top protein biomarkers significantly associated with vaping or dual use. The distribution of the top significantly associated protein biomarkers in the analysis of vapers or dual users versus former smokers. DPYL5 is significantly elevated in vapers relative to all other vaping/smoking groups ($p<0.005$). KLK13 is significantly associated with vapers, dual users, and current smokers

when compared to former smokers. s-ICAM5 and Secretoglobin family member 3A member 1 were significantly associated with dual users and current smokers but not vapers when compared to former smokers.

Figure 4. Correlation of biomarker responses between vapers, dual users, and current smokers. Comparison of the biomarker association profiles demonstrates that while the dual user and current smoker profiles are very similar, the vaping biomarker profile is more distinct. For the RNA and protein biomarker analysis of vaping/smoking groups versus former smokers, the effect sizes for each pair of comparisons were plotted and the Pearson correlation of effect sizes was calculated. In each pairwise comparison, only biomarkers significant in at least one of analyses were analyzed. In row A, vaping-associated RNA biomarker effects are compared to current smoker effects (left), dual user effects (middle), and then dual user and current smoker effects are compared (right). In row B, the corresponding protein biomarker effects are compared.

Figure 5. Top protein vaping and dual use biomarkers significantly associated with overall mortality. The dual use-associated proteins Growth hormone receptor, MIC-1, and HE4 were significantly associated with overall mortality. KLK-13 was the only vaping associated biomarker that was also associated mortality. All associations were significant at a false discovery rate of 10%.

Figure 6. Concordance analysis of biomarker associations to vaping/dual use and adverse health outcomes. For protein biomarkers that were significantly associated with at least one health outcome and vaping (n=2) or dual use (n=86), we plotted the effect of the exposure (vaping or dual use) against the effect with respect to the health outcome. Since some biomarkers were significantly associated with multiple health outcomes, the total number of analyzed associations was 246. The top panel shows the relationship between exposure effect and change FEV1 (ml/yr) where each of the 107 associations was concordant for loss of FEV1. Change in FEV1 is calculated as visit 3 value - visit 2 value, meaning negative values indicate loss of lung function. The bottom panel shows the relationship between exposure effect and hazard ratio for all cause mortality, respiratory mortality, exacerbations, or incident cardiovascular disease. 117 of 139 associations were concordant for higher health risk. Exposure effect is the beta coefficient from the dual use versus former smokers analysis, except for DPYL5 and KLK13 which is from the vapers versus former smokers analysis.

References

1 Gentzke AS, Wang TW, Jamal A, *et al*. Tobacco Product Use Among Middle and High School Students - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:1881–8.

2 Mayer M, Reyes-Guzman C, Grana R, *et al*. Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. *JAMA Netw Open* 2020;**3**:e2020694.

3 Li D, Sundar IK, McIntosh S, *et al.* Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. Tobacco Control. 2019;:tobaccocontrol – 2018. doi:10.1136/tobaccocontrol-2018-054694

4 Yao T, Max W, Sung H-Y, *et al.* Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. *PLoS One* 2017;**12**:e0187399.

5 St Helen G, Eaton DL. Public Health Consequences of e-Cigarette Use. *JAMA Intern Med* 2018;**178**:984–6.

6 Smith ML, Gotway MB, Crotty Alexander LE, *et al*. Vaping-related lung injury. *Virchows Arch* 2021;**478**:81–8.

7 Cherian SV, Kumar A, Estrada-Y-Martin RM. E-Cigarette or Vaping Product-Associated Lung Injury: A Review. *Am J Med* 2020;**133**:657–63.

8 Hammond D, Reid JL, Rynard VL, *et al*. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;**365**:l2219.

9 Miech R, Johnston L, O'Malley PM, *et al.* Trends in Adolescent Vaping, 2017–2019. *N Engl J Med* 2019;**381**:1490–1.

10 Miech R, Johnston L, O'Malley PM, *et al.* Adolescent vaping and nicotine use in 2017-2018 - U.s. national estimates. *N Engl J Med* 2019;**380**:192–3.

11 Aronson JK. Research priorities in biomarkers and surrogate end-points. *Br J Clin Pharmacol* 2012;**73**:900–7.

12 FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and Other Tools) Resource*. Food and Drug Administration (US) 2016.

13 Regan EA, Hokanson JE, Murphy JR, *et al.* Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;**7**:32–43.

14 Gold L, Ayers D, Bertino J, *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* 2010;**5**:e15004.

15 Gillenwater LA, Kechris KJ, Pratte KA, *et al.* Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema. *Metabolites* 2021;**11**. doi:10.3390/metabo11030161

16 Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**:e47.

17 Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc* 1995;**57**:289–300.

18 Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N. Artyomov, Alexey Sergushichev. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. biorxiv. 2021. doi:10.1101/060012

19 Singh KP, Lawyer G, Muthumalage T, *et al.* Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. *ERJ Open Res* 2019;**5**. doi:10.1183/23120541.00182-2019

20 Goniewicz ML, Smith DM, Edwards KC, *et al.* Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. *JAMA Netw Open* 2018;**1**:e185937.

21 Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicology Reports. 2021;**8**:282–94. doi:10.1016/j.toxrep.2021.01.014

22 Neil Sherwood. TobaccoTactics. 2020.https://tobaccotactics.org/wiki/neil-sherwood/ (accessed 26 Jun 2022).

23 Tommasi S, Caliri AW, Caceres A, *et al.* Deregulation of Biologically Significant Genes and Associated Molecular Pathways in the Oral Epithelium of Electronic Cigarette Users. *Int J Mol Sci* 2019;**20**. doi:10.3390/ijms20030738

24 Kaur G, Singh K, Maremanda KP, *et al.* Differential plasma exosomal long non-coding RNAs expression profiles and their

emerging role in E-cigarette users, cigarette, waterpipe, and dual smokers. *PLoS One* 2020;**15**:e0243065.

25 Huang C-S, Ho J-Y, Chiang J-H, *et al.* Exosome-Derived LINC00960 and LINC02470 Promote the Epithelial-Mesenchymal Transition and Aggressiveness of Bladder Cancer Cells. *Cells* 2020;**9**. doi:10.3390/cells9061419

26 Bozier J, Chivers EK, Chapman DG, *et al.* The Evolving Landscape of e-Cigarettes: A Systematic Review of Recent Evidence. *Chest* 2020;**157**:1362–90.


Log cotinine raw area count
10
15
20
25
CS
Dual
Vaper
FS


GPR15
log normalized count
CS
Dual
FS
Vapers


NPHP1
log normalized count
CS
Dual
FS
Vapers


LINC02470
log normalized count
CS
Dual
FS
Vapers


DPYL5
normalized RFU
3
2
1
0
-1
-2
-3
CS
Dual
FS
Vapers


KLK13
normalized RFU
2
0
-2
CS
Dual
FS
Vapers


sICAM-5
normalized RFU
3
2
1
0
-1
-2
-3
CS
Dual
FS
Vapers


Secretoglobin family 3A member 1
normalized RFU
2
0
-2
CS
Dual
FS
Vapers


A
vape
smoke
both
Smoking effect size
Vaping effect size
UNC02470
r = 0.44
Dual use effect size
r = 0.33
r = 0.76
B
DPYLS
r = 0.26
r = 0.23
r = 0.88

Growth hormone receptor
normalized RFU
2
0
-2
alive
dead


MIC-1
normalized RFU
2
0
-2
alive
dead


HE4
normalized RFU
2
0
-2
alive
dead


KLK13
normalized RFU
3
2
1
0
-1
-2
-3
alive
dead


delta FEV1 effect (ml/yr per unit expression)
6
4
2
0
-2
-4
-6
decreased in exposure, less loss in FEV1
increased in exposure, more loss in FEV1
-1.0
-0.5
0.0
0.5
1.0
Exposure effect


HR per unit expression
2.0
1.5
1.0
0.5
0.0
increased in exposure, higher risk
decreased in exposure, lower risk
-1.0
-0.5
0.0
0.5
1.0
Exposure effect